Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    Ichor Awarded DARPA ADEPT: PROTECT Contract

    By Global Biodefense StaffNovember 18, 2014
    Notable CBRN and Biodefense Contracts
    Share
    Facebook LinkedIn Reddit Email

    Ichor Medical Systems of San Diego has been awarded a contract through the Defense Advanced Research Projects Agency (DARPA) and supported by the U.S. Army Research Office for up to $20.2 million of funding over five years, including a base period award of $8.6M.

    The award is part of a DARPA program called Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT: PROTECT) aimed at developing new platform technologies that could be safely and rapidly deployed to the U.S. population and military personnel to provide immediate protection in the event of an infectious outbreak or biological weapons attack.

    The program will fund the development and clinical assessment of Ichor’s TriGrid electroporation system as a DNA-based antibody delivery platform to produce protective antibodies for passive immunoprophylaxis.

    While active immunization with traditional vaccines is effective at stimulating the immune system to generate protective antibodies, such responses are not immediate and may require multiple doses of the vaccine.

    In contrast, the TriGrid technology could be used to bypass the immune system to directly deliver DNA sequences encoding protective antibodies into an infected or exposed individual. This approach would result in rapid production of antibodies by the individual providing immediate protection against the pathogen.

    “We are excited for this new opportunity with the Department of Defense to apply the TriGrid technology to another area of high priority for national security,” said Bob Bernard, Ichor CEO. “Whether to address unknown bioterrorist threats or pandemic disease, success of this approach would revamp traditional vaccine processes and position the TriGrid favorably for use in other broad spectrum biodefense and pandemic applications.”

    Source: Ichor press release, adapted. TriGrid is a trademarked, protected term by Ichor Medical Systems

    Awards DARPA
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleCall for Proposals on Ebola and Other Filoviruses
    Next Article Joint Biological Tactical Detection System Market Survey

    Related Stories

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023

    Call for Experts: Smallpox Medical Countermeasures

    October 28, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.